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Abstract

Results

Poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) are polymers approved by
the United States’ Food and Drug Administration due to their biocompatibility with humans.
Drugs for various medical treatments have been encapsulated in PLGA-PEG nanoparticles for
targeted delivery and reducing unwanted side effects. In this research, a flow synthesis method
for PLGA-PEG nanoparticles with FoxO1 inhibitors and adipose vasculature targeting agent
were studied. These drugs inhibit the FoxO1 pathway targeting white adipose tissues and
converting them from an energy storing state to an energy burning state. A set of nanoparticles
including PLGA and PLGA-PEG-P3 unloaded and drug loaded were generated. The particles
were characterized by Dynamic Light Scattering, Fluorescence Spectroscopy, Transmission
Electron Microscopy and Dialysis to measure hydrodynamic diameter, size distribution, zeta
potential, stability, yield and encapsulation efficiency.
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Figure 3. Method distribution for
Nanoparticle synthesis.
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Figure 5. Size of PLGA
nanoparticles.
Size Measurements for
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Figure 2. Representation of
PLGA-PEG-P3-AS1842856 nanoparticle.
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• Around one third of the United States
population is obese.
• The medical approach to treating this disorder is
mainly focused on diet and exercise.
• Inhibition of the FoxO1 pathway allows for
browning of adipose tissue to occur.
• Poly(lactic-co-glycolic acid) and polyethylene
glycol are polymers used in the synthesis of
nanoparticles for targeted drug delivery.
• Flow chemistry allows for more uniform particle
formation as well as repeatability across batches.
• Our synthesis approach was compared to over
270 research articles using information
extraction tools.
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Figure 4. TEM image of PLGA
nanoparticles.

Figure 1. Schematic of the
browning of white adipose tissue.1
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Figure 6. TEM image of
PLGA-PEG-P3 nanoparticles.
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Figure 7. Size of PLGA-PEG-P3
nanoparticles.

Dynamic Light Scattering
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Nanoparticles
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Endotoxin Levels

Control the release profile of the drug loaded nanoparticles in vitro.
Develop PLGA-PEG loaded and unloaded nanoparticles for comparison.
Determination of peptide conjugation efficiency.
Carry out in vivo models with the developed nanoparticles.
Manage the endotoxin levels in the nanoparticles.
Study alternative syntheses such as water/oil/water emulsion or liposomal
encapsulation for the other more hydrophilic drugs.
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• PLGA-PEG-P3-AS1842856 nanoparticles had a range of sizes from
142.4 ±0.4 d.nm to 208.7 ±3.5 d.nm. This was confirmed with TEM
imaging.
• The polydispersity index was less than 0.500 for all the samples, ranging
from 0.057 ±0.021 to 0.369 ±0.038.
• Zeta potential values for the nanoparticles synthesized ranged from
-4.330mV ±0.214 mV to 13.40mV ± 1.89mV
• Stability testing indicated that the nanoparticles are stable for at least a
month after production, based on particle size measurements.
• When comparing both PLGA and PLGA-AS1842856 nanoparticles it
was evident that the drug is being encapsulated due to the change in size
and fluorescence intensity. This was also the case with PLGA-PEG-P3
samples.
• Through fluorescence spectroscopy, the encapsulation efficiency was
determined to be 100% for both AS1842856 drug loaded nanoparticles
synthesized.
• Elevated endotoxin levels were measured in the synthesized particle
suspensions.
• No nanoprecipitation occurred when using the same synthesis approach
for two other hydrophilic drugs.

Figure 8. Decision tree based on nanoparticle data extracted from scientific papers.
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